2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-W008915R
    Cytidine 5'-diphosphate trisodium salt (Standard) 34393-59-4
    Cytidine 5'-diphosphate (trisodium salt) (Standard) is the analytical standard of Cytidine 5'-diphosphate (trisodium salt). This product is intended for research and analytical applications. Cytidine 5'-diphosphate trisodium salt (CDP) is produced by the transfer of phosphoryl group from ATP to cytidine monophosphate (CMP) catalyzed by uridine monophosphate kinase (UMPK). Cytidine 5′-diphosphate can be used to produce Cytidine triphosphate (CTP) for synthesis of DNA and RNA[1][2].
    Cytidine 5'-diphosphate trisodium salt (Standard)
  • HY-W019901B
    Anhydrous calcium sulfate (97%) 7778-18-9 99.40%
    Anhydrous calcium sulfate (97%) serves as an oil-based drilling fluid additive and an osteogenic material. Anhydrous calcium sulfate (97%) increases the plastic viscosity, yield point, apparent viscosity and gel strength of oil-based drilling fluids. Anhydrous calcium sulfate (97%) upregulates the expression of bone-related genes FOSL1, RUNX2 and SPP1. Anhydrous calcium sulfate (97%) significantly affects the behavior of dental pulp stem cells, enhancing their proliferation, differentiation and matrix deposition.
    Anhydrous calcium sulfate (97%)
  • HY-W053787S
    1-Methylhistamine-d3 dihydrochloride 344299-49-6 99.91%
    1-Methylhistamine-d3 (dihydrochloride) is the deuterium labeled 1-Methylhistamine (dihydrochloride). 1-Methylhistamine dihydrochloride is a histamine metabolite.
    1-Methylhistamine-d3 dihydrochloride
  • HY-W540188A
    Calcium mesoxalate trihydrate 98.5%
    Calcium mesoxalate trihydrate (Ketomalonic acid; Mesoxalic acid; Oxomalonic acid) can promote B cell proliferation and has potential anti-diabetic activity. Derivatives of Calcium mesoxalate trihydrate also inhibit the translocation of HIC-1 reverse transcriptase.
    Calcium mesoxalate trihydrate
  • HY-W013636S2
    2-Ketoglutaric acid-d6 1173021-86-7 98.62%
    2-Ketoglutaric acid-d6 (Alpha-Ketoglutaric acid-d6) is the deuterium labeled 2-Ketoglutaric acid (HY-W013636). 2-Ketoglutaric acid is an intermediate in the production of ATP or GTP in the Krebs cycle. 2-Ketoglutaric acid also acts as the major carbon skeleton for nitrogen-assimilatory reactions. 2-Ketoglutaric acid is a reversible inhibitor of tyrosinase (IC50=15 mM).
    2-Ketoglutaric acid-d6
  • HY-14880B
    Bavisant dihydrochloride hydrate 1103522-80-0 98.07%
    Bavisant (JNJ31001074AAC) dihydrochloride hydrate is an orally active, potent, brain-penetrating and highly selective antagonist of the histamine H3 receptor. Bavisant dihydrochloride hydrate can be used for attention-deficit hyperactivity disorder (ADHD) research.
    Bavisant dihydrochloride hydrate
  • HY-13720
    Pergolide 66104-22-1 98.59%
    Pergolide (LY127809 free base), an Ergoline derivative, is a potent and orally active dopamine D1 and D2 receptor agonist. Pergolide can be used for Parkinson's disease and hyperprolactinaemia research.
    Pergolide
  • HY-D1050
    DNP-X, SE 82321-04-8 98.47%
    DNP-X, SE (6-(2,4-Dinitrophenyl)aminohexanoic acid, succinimidyl ester), the DNP-X acid modified by succinimidyl ester, is an amine-reactive building block for developing a probe, which can be recognized by anti-DNP antibodies. DNP-X, SE (6-(2,4-Dinitrophenyl)aminohexanoic acid, succinimidyl ester) is also an excellent amine-reactive FRET quencher paired with Trp or Tyr.
    DNP-X, SE
  • HY-128578
    KPLH1130 906669-07-6 99.86%
    KPLH1130 is a pyruvate dehydrogenase kinase (PDK) inhibitor. KPLH1130 potently inhibits M1 macrophage polarization by reducing the expression of pro-inflammatory cytokines, decreasing the levels of M1 phenotype markers (HIF-1α, iNOS) and nitric oxide (NO) production. KPLH1130 prevents the reduction of mitochondrial oxygen consumption rate (OCR) induced by inflammatory stimuli (LPS ((HY-D1056) + IFN-γ) in various macrophage types. KPLH1130 improves glucose tolerance in HFD-fed mice. KPLH1130 can be used for the study of obesity-associated metabolic disorders and other inflammatory conditions.
    KPLH1130
  • HY-134001
    CBR-470-2 2416095-00-4 99.45%
    CBR-470-2, a glycine-substituted analog, can activate NRF2 signaling. CBR-470-2 can be used for the research of modulation glycolysis.
    CBR-470-2
  • HY-136773
    KER047 2248154-85-8 98.80%
    KER047 (ALK2-IN-4) is a potent activin receptor-like kinase-2 (ALK2) inhibitor. KER047 can be used for the research of metabolic disease, such as fibrodysplasia ossificans progressiva (FOP).
    KER047
  • HY-145605
    Vutiglabridin 1800188-47-9 99.30%
    Vutiglabridin (HSG4112), a racemic compound, is a potent anti-obesity agent. Vutiglabridin, an optimized structural analog of Glabridin, markedly supersedes Glabridin in weight reduction efficacy and chemical stability.
    Vutiglabridin
  • HY-149831
    ZLY28 3004676-77-8 99.95%
    ZLY28 is the first-in-class intestinal restricted and orally active FXR and FABP1 dual modulator. ZLY28 also is a novel anti-NASH agent. ZLY28 can be used for the research of nonalcoholic steatohepatitis (NASH).
    ZLY28
  • HY-163689
    Vicadrostat 1868065-21-7 98.67%
    Vicadrostat (BI 690517) is an orally active aldosterone synthase (aldosterone synthase) inhibitor, with IC50 values of 19 nM, 16 nM, and 18 μM against human, cynomolgus monkey, and rat aldosterone synthase, respectively. Vicadrostat has an in vivo IC50 of 25 nM for aldosterone synthesis. Vicadrostat exhibits high selectivity for cortisol synthase; it reduces aldosterone production and decreases plasma aldosterone levels. Vicadrostat can be used in the research of chronic kidney disease, heart failure, and hypertension.
    Vicadrostat
  • HY-165607S
    MCB-22-174 3058199-58-6 99.78%
    MCB-22-174 is a deuterated Piezo1 agonist, with an EC50 value of 6.28 μM. MCB-22-174 remarkably activates the CaMKII/ERK signaling pathway and initiates Ca2+ influx in rMSCs. MCB-22-174 significantly decreases the expression of chondrogenesis markers (Comp, Acan) and adipogenesis markers (Lpl, Fabp4) in MSCs. MCB-22-174 can effectively improve bone quality in hind-limb unloading (HU) model rats. MCB-22-174 can be used for the study of disuse osteoporosis (OP).
    MCB-22-174
  • HY-B0228S4
    Adenosine-1′-13C 201996-55-6
    Adenosine-1′-13C is the 13C labeled Adenosine. Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiolo
    Adenosine-1′-13C
  • HY-W012926S1
    Dihydrouracil-d4 334473-41-5 99.97%
    Dihydrouracil-d4 is the deuterium labeled Dihydrouracil. Dihydrouracil (HY-W012926), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient.
    Dihydrouracil-d4
  • HY-16255
    Imirestat 89391-50-4 99.59%
    Imirestat (AL 1576) is an aldose reductase inhibitor, used for the treatment of diabetes.
    Imirestat
  • HY-114404
    SJFα 2254609-27-1 99.61%
    SJFα is a selective p38α PROTAC degrader with a DC50 of 7.16   nM and Dmax of 97.4%. SJFα is far less effective at degrading p38δ (DC50 = 299 nM). SJFαcan be used for the research of cancer, such as breast cancer.
    SJFα
  • HY-131334
    AMPK activator 4 2493239-46-4 98.64%
    AMPK activator 4 is a potent AMPK activator without inhibition of mitochondrial complex I. AMPK activator 4 selectively activates AMPK in the muscle tissues. AMPK activator 4 dose-dependently improves glucose tolerance in normal mice, and significantly lowers fasting blood glucose level and ameliorates insulin resistance in db/db diabetic mice. Anti-hyperglycemic effect.
    AMPK activator 4
Cat. No. Product Name / Synonyms Application Reactivity